AtaiBeckley Q1 revenue falls, net loss widens on higher expenses

AtaiBeckley

12/05/2026 13:08

Overview

US biotech firm's Q1 revenue fell yr/yr, net loss widened

Higher R&D and G&A expenses drove increased net loss in Q1

Company expects cash to fund operations through anticipated Phase 3 topline readouts into 2029

Outlook

AtaiBeckley expects to initiate BPL-003 Phase 3 program for depression in Q2 2026

Company anticipates VLS-01 Phase 2 topline results in Q4 2026

AtaiBeckley expects cash to fund operations through BPL-003 Phase 3 topline readouts, with runway into 2029

Result Drivers

R&D SPENDING - Higher clinical development and personnel costs for BPL-003, VLS-01, and EMP-01 drove increased R&D expenses

G&A EXPENSES - Increased legal, intellectual property, professional service, and personnel costs raised G&A expenses

Company press release: ID:nGNX8GlQWL

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.08
Q1 Net Income
-$29.80 mln
Q1 Operating Expenses
$31.86 mln
Q1 Operating Income
-$30.90 mln
Q1 Pretax Profit
-$29.78 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for AtaiBeckley Inc is $14.50, about 258.9% above its May 11 closing price of $4.04

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)